The Chemours Company Earnings Call Transcripts
Fiscal Year 2026
-
First quarter 2026 results surpassed expectations, led by strong TSS and TT segment performance, robust pricing, and disciplined execution. Guidance for the year is reaffirmed, with continued focus on operational reliability, cost control, and balance sheet strength.
Fiscal Year 2025
-
Strong Q4 cash flow and record TSS Opteon sales drove results, with 2026 guidance targeting 3%-5% sales growth and $800M-$900M Adjusted EBITDA. Strategic asset sales and cost initiatives support deleveraging and improved free cash flow conversion.
-
Q3 2025 results exceeded expectations, led by strong Opteon sales and cost controls, while TiO₂ demand remained weak. Guidance anticipates sequential sales and EBITDA declines in Q4, but 2026 is expected to bring growth and improved cash flow.
-
Q2 2025 results exceeded expectations with strong growth in TSS and progress on environmental settlements. Operational disruptions in TT and APM impacted results but are being addressed. Full-year guidance remains robust, with >5% sales growth expected in 2026, led by TSS.
-
Q1 saw strong Opteon demand and cost discipline, but lower pricing and restructuring led to a net loss. Guidance for 2025 was refined, with improved outlooks for TSS and TT, a dividend cut to boost flexibility, and a focus on operational excellence and growth initiatives.
-
Chemours outlined its growth strategy, emphasizing cost reductions, portfolio optimization, and innovation in refrigerants and data center cooling. The company is managing PFAS liabilities, expects double-digit TSS growth in 2025, and remains focused on operational excellence and market recovery.
Fiscal Year 2024
-
Q4 and full-year 2024 results exceeded Adjusted EBITDA expectations, driven by cost savings and strong Opteon™ refrigerant growth, despite macro headwinds. 2025 guidance anticipates improved earnings, continued cost reductions, and disciplined capital allocation.
-
Third-quarter results showed strong operational execution, record Opteon sales, and robust cost savings, though pricing pressures and a non-cash impairment led to a net loss. The refreshed strategy targets $250M+ in cost savings and growth in high-value markets, with continued focus on litigation resolution and disciplined capital allocation.
-
Q2 2024 saw lower sales and earnings due to pricing pressure, regulatory impacts, and a major production disruption, but strong Opteon growth and cost savings offset some headwinds. The outlook anticipates continued challenges in Q3, with recovery expected as regulatory and market dynamics improve.